<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29263886</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2059-0105</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.</ArticleTitle><Pagination><StartPage>31</StartPage><MedlinePgn>31</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">31</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-017-0033-5</ELocationID><Abstract><AbstractText>Targeting model antigens (Ags) to Clec9A on DC has been shown to induce, not only cytotoxic T cells, but also high levels of Ab. In fact, Ab responses against immunogenic Ag were effectively generated even in the absence of DC-activating adjuvants. Here we tested if targeting weakly immunogenic putative subunit vaccine Ags to Clec9A could enhance Ab responses to a level likely to be protective. The proposed "universal" influenza Ag, M2e and the enterovirus 71 Ag, SP70 were linked to anti-Clec9A Abs and injected into mice. Targeting these Ags to Clec9A greatly increased Ab titres. For optimal responses, a DC-activating adjuvant was required. For optimal responses, a boost injection was also needed, but the high Ab titres against the targeting construct blocked Clec9A-targeted boosting. Heterologous prime-boost strategies avoiding cross-reactivity between the priming and boosting targeting constructs overcame this limitation. In addition, targeting small amounts of Ag to Clec9A served as an efficient priming for a conventional boost with higher levels of untargeted Ag. Using this Clec9A-targeted priming, conventional boosting strategy, M2e immunisation protected mice from infection with lethal doses of influenza H1N1 virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hae-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0004 1936 7857</Identifier><Identifier Source="GRID">grid.1002.3</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Biomedical Research, Burnet Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2224 8486</Identifier><Identifier Source="GRID">grid.1056.2</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Peck S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0004 1936 7857</Identifier><Identifier Source="GRID">grid.1002.3</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Biomedical Research, Burnet Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2224 8486</Identifier><Identifier Source="GRID">grid.1056.2</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavishna</LastName><ForeName>Ranmali</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ker</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jinhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Conrad E Z</ForeName><Initials>CEZ</Initials><AffiliationInfo><Affiliation>DSO National Laboratories, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0004 0640 7311</Identifier><Identifier Source="GRID">grid.410760.4</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Brendon J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>DSO National Laboratories, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0004 0640 7311</Identifier><Identifier Source="GRID">grid.410760.4</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacAry</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caminschi</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0004 1936 7857</Identifier><Identifier Source="GRID">grid.1002.3</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Biomedical Research, Burnet Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2224 8486</Identifier><Identifier Source="GRID">grid.1056.2</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2179 088X</Identifier><Identifier Source="GRID">grid.1008.9</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shortman</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Biomedical Research, Burnet Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2224 8486</Identifier><Identifier Source="GRID">grid.1056.2</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="GRID">grid.1042.7</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, University of Melbourne, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2179 088X</Identifier><Identifier Source="GRID">grid.1008.9</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.</Affiliation><Identifier Source="ISNI">0000 0001 2180 6431</Identifier><Identifier Source="GRID">grid.4280.e</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahoud</LastName><ForeName>Mireille H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0004 1936 7857</Identifier><Identifier Source="GRID">grid.1002.3</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Biomedical Research, Burnet Institute, Melbourne, VIC Australia.</Affiliation><Identifier Source="ISNI">0000 0001 2224 8486</Identifier><Identifier Source="GRID">grid.1056.2</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29263886</ArticleId><ArticleId IdType="pmc">PMC5674066</ArticleId><ArticleId IdType="doi">10.1038/s41541-017-0033-5</ArticleId><ArticleId IdType="pii">33</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kreutz MTP, Figdor CG. Targeting dendritic cells-why bother? Blood. 2013;121:2836&#x2013;2844. doi: 10.1182/blood-2012-09-452078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-09-452078</ArticleId><ArticleId IdType="pubmed">23390195</ArticleId></ArticleIdList></Reference><Reference><Citation>Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 2012;33:71&#x2013;77. doi: 10.1016/j.it.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2011.10.007</ArticleId><ArticleId IdType="pubmed">22153931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifaz LC, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T-cell vaccination. J. Exp. Med. 2004;199:815&#x2013;824. doi: 10.1084/jem.20032220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20032220</ArticleId><ArticleId IdType="pmc">PMC2212731</ArticleId><ArticleId IdType="pubmed">15024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscardin SB, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 2006;203:599&#x2013;606. doi: 10.1084/jem.20051639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20051639</ArticleId><ArticleId IdType="pmc">PMC2118236</ArticleId><ArticleId IdType="pubmed">16505139</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasan S, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B&#x2019;/C candidate vaccine. PLoS ONE. 2010;5:e8816. doi: 10.1371/journal.pone.0008816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008816</ArticleId><ArticleId IdType="pmc">PMC2810329</ArticleId><ArticleId IdType="pubmed">20111599</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasan S, et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B&#x2019; HIV-1 candidate vaccine. PLoS ONE. 2010;5:e8617. doi: 10.1371/journal.pone.0008617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008617</ArticleId><ArticleId IdType="pmc">PMC2799527</ArticleId><ArticleId IdType="pubmed">20111582</ArticleId></ArticleIdList></Reference><Reference><Citation>Caminschi I, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 2008;112:3264&#x2013;3273. doi: 10.1182/blood-2008-05-155176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-05-155176</ArticleId><ArticleId IdType="pmc">PMC2569177</ArticleId><ArticleId IdType="pubmed">18669894</ArticleId></ArticleIdList></Reference><Reference><Citation>Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+dendritic cells and a subset of monocytes. J. Biol. Chem. 2008;283:16693&#x2013;16701. doi: 10.1074/jbc.M709923200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M709923200</ArticleId><ArticleId IdType="pmc">PMC2562446</ArticleId><ArticleId IdType="pubmed">18408006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho D, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 2008;118:2098&#x2013;2110. doi: 10.1172/JCI34584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI34584</ArticleId><ArticleId IdType="pmc">PMC2391066</ArticleId><ArticleId IdType="pubmed">18497879</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 2014;14:571&#x2013;578. doi: 10.1038/nri3712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3712</ArticleId><ArticleId IdType="pmc">PMC4638219</ArticleId><ArticleId IdType="pubmed">25033907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shortman K, Heath WR. The CD8+sdendritic cell subset. Immunol. Rev. 2010;234:18&#x2013;31. doi: 10.1111/j.0105-2896.2009.00870.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2009.00870.x</ArticleId><ArticleId IdType="pubmed">20193009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroczek RA, Henn V. The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol. 2012;3:14. doi: 10.3389/fimmu.2012.00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00014</ArticleId><ArticleId IdType="pmc">PMC3342032</ArticleId><ArticleId IdType="pubmed">22566900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JG, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36:646&#x2013;657. doi: 10.1016/j.immuni.2012.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.009</ArticleId><ArticleId IdType="pubmed">22483802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahrens S, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36:635&#x2013;645. doi: 10.1016/j.immuni.2012.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.008</ArticleId><ArticleId IdType="pubmed">22483800</ArticleId></ArticleIdList></Reference><Reference><Citation>Iborra S, et al. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J. Clin. Invest. 2012;122:1628&#x2013;1643. doi: 10.1172/JCI60660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60660</ArticleId><ArticleId IdType="pmc">PMC3336985</ArticleId><ArticleId IdType="pubmed">22505455</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HY, et al. Evolution of B cell responses to Clec9A-targeted antigen. J. Immunol. 2013;191:4919&#x2013;4925. doi: 10.4049/jimmunol.1301947.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301947</ArticleId><ArticleId IdType="pubmed">24123689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahoud MH, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J. Immunol. 2011;187:842&#x2013;850. doi: 10.4049/jimmunol.1101176.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101176</ArticleId><ArticleId IdType="pubmed">21677141</ArticleId></ArticleIdList></Reference><Reference><Citation>Caminschi I, et al. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice. Mol. Immunol. 2012;50:9&#x2013;17. doi: 10.1016/j.molimm.2011.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2011.11.008</ArticleId><ArticleId IdType="pubmed">22209163</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur. J. Immunol. 2015;45:854&#x2013;864. doi: 10.1002/eji.201445127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201445127</ArticleId><ArticleId IdType="pubmed">25487143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tullett KM, et al. Targeting CLEC9A delivers antigen to human CD141+DC for CD4+and CD8+T cell recognition. JCI Insight. 2016;1:e87102. doi: 10.1172/jci.insight.87102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.87102</ArticleId><ArticleId IdType="pmc">PMC5033826</ArticleId><ArticleId IdType="pubmed">27699265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, et al. Targeting antigen to Clec9A primes follicular Th cell memory responses capable of robust recall. J. Immunol. 2015;195:1006&#x2013;1014. doi: 10.4049/jimmunol.1500767.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500767</ArticleId><ArticleId IdType="pubmed">26101322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus. Genes. 2011;42:1&#x2013;8. doi: 10.1007/s11262-010-0547-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-010-0547-7</ArticleId><ArticleId IdType="pubmed">21082230</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L, Cho KJ, Fiers W, Saelens X. Vaccines (Basel) 2015. M2e-based universal influenza A vaccines; pp. 105&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494237</ArticleId><ArticleId IdType="pubmed">26344949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Zhou L, Chen YH. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine. 2012;30:3463&#x2013;3469. doi: 10.1016/j.vaccine.2012.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.021</ArticleId><ArticleId IdType="pubmed">22446634</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus. Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes. Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Pelayo MC, Bachy VS, Kaveh DA, Hogarth PJ. BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection. Tuberculosis (Edinb). 2015;95:48&#x2013;53. doi: 10.1016/j.tube.2014.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tube.2014.10.012</ArticleId><ArticleId IdType="pubmed">25467292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Infection of inbred BALB/c and C57BL/6 and outbred Institute of Cancer Research mice with the emerging H7N9 avian influenza virus. Emerg. Microbes Infect. 2013;2:e50. doi: 10.1038/emi.2013.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2013.50</ArticleId><ArticleId IdType="pmc">PMC3821289</ArticleId><ArticleId IdType="pubmed">26038485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CE, Lim AP, MacAry PA, Hanson BJ. The role of phage display in therapeutic antibody discovery. Int. Immunol. 2014;26:649&#x2013;657. doi: 10.1093/intimm/dxu082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu082</ArticleId><ArticleId IdType="pmc">PMC7185696</ArticleId><ArticleId IdType="pubmed">25135889</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser CC, et al. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine. 2014;32:2896&#x2013;2903. doi: 10.1016/j.vaccine.2014.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.02.024</ArticleId><ArticleId IdType="pubmed">24583006</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492&#x2013;503. doi: 10.1016/j.immuni.2010.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.002</ArticleId><ArticleId IdType="pmc">PMC3420356</ArticleId><ArticleId IdType="pubmed">21029960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009;21:346&#x2013;351. doi: 10.1016/j.coi.2009.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2009.05.016</ArticleId><ArticleId IdType="pmc">PMC3743086</ArticleId><ArticleId IdType="pubmed">19500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournillier A, et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J. Infect. Dis. 2013;208:1008&#x2013;1019. doi: 10.1093/infdis/jit267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit267</ArticleId><ArticleId IdType="pmc">PMC3749006</ArticleId><ArticleId IdType="pubmed">23776192</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari A, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008;205:63&#x2013;77. doi: 10.1084/jem.20071331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20071331</ArticleId><ArticleId IdType="pmc">PMC2234371</ArticleId><ArticleId IdType="pubmed">18195071</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett AJ, et al. Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional &#x201c;danger&#x201d;. Eur. J. Immunol. 2005;35:2815&#x2013;2825. doi: 10.1002/eji.200526100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200526100</ArticleId><ArticleId IdType="pubmed">16143986</ArticleId></ArticleIdList></Reference><Reference><Citation>Idoyaga JLA, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. USA. 2011;108:2384&#x2013;2389. doi: 10.1073/pnas.1019547108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019547108</ArticleId><ArticleId IdType="pmc">PMC3038758</ArticleId><ArticleId IdType="pubmed">21262813</ArticleId></ArticleIdList></Reference><Reference><Citation>Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 2000;164:2978&#x2013;2986. doi: 10.4049/jimmunol.164.6.2978.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.6.2978</ArticleId><ArticleId IdType="pubmed">10706685</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>